Nuvo Pharmaceuticals Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jesse F. Ledger
- Full Time Employees
- 101
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 6733 Mississauga Road Mississauga ON Canada L5N 6J5
- IPO Date
- Apr 26, 2010
- Website
- miravohealthcare.com
- Similar Companies
- Business
- Nuvo Pharmaceuticals Inc. (Ticker: MRVFF), formerly known as Miravo Healthcare, develops, markets, and sells innovative pharmaceutical products focused on neurology, gastroenterology, and dermatology. The company offers a portfolio of branded prescription drugs including Trevica (treprostinil) for pulmonary arterial hypertension; Siliq (brodalumab) for moderate-to-severe plaque psoriasis; Rectiv (nitroglycerin) for moderate-to-severe pain associated with chronic anal fissure; and a range of generic and specialty products such as NDA-approved formulations in pain management, allergy, and anti-infectives. Nuvo operates primarily in North America through its commercial infrastructure, with manufacturing and distribution capabilities supporting both branded and generic segments; it targets healthcare providers, pharmacies, and specialty channels in the United States and Canada. Founded in 2016 and headquartered in Mississauga, Ontario, Canada, the company pursues growth through in-licensing, partnerships, and lifecycle management of differentiated therapies. In late 2024, Nuvo underwent a significant rebranding from Miravo Healthcare to better align with its expanded pharmaceutical focus following strategic divestitures and pipeline advancements. Recent developments include the advancement of its teprotumumab biosimilar candidate into Phase 3 clinical trials for thyroid eye disease treatment and ongoing commercialization efforts for Trevica, launched in partnership with Insmed Incorporated to leverage established delivery systems.
Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF)
Nuvo Pharmaceuticals Inc. (MRVFF) Q3 2022 Earnings Call Transcript
Nuvo Pharmaceuticals Inc. (MRVFF) CEO Jesse Ledger on Q2 2022 Results - Earnings Call Transcript
Miravo Healthcare™ Announces Second Quarter 2022 Results Release Date and Conference Call Details
Nuvo Pharmaceuticals Inc. (MRVFF) CEO Jesse Ledger on Q4 2021 Results - Earnings Call Transcript
Miravo Healthcare(TM) to Present at Q1 Virtual Investor Summit
Miravo Healthcare™ to Present at Q1 Virtual Investor Summit
Miravo Healthcare™ to Host Investor Webcast on December 2, 2021 at 2:00 p.m. ET
Nuvo Pharmaceuticals' (MRVFF) CEO Jesse Ledger on Q3 2021 Results - Earnings Call Transcript
Miravo Healthcare™ Announces Third Quarter 2021 Results Release Date and Conference Call Details
Miravo Healthcare™ Announces Receipt of Health Canada Notice of Compliance for the Pediatric Use of Blexten®
Nuvo Pharmaceuticals Inc (MRVFF) CEO Jesse Ledger on Q2 2021 Results - Earnings Call Transcript
Miravo Healthcare™ Announces Second Quarter 2021 Results
Miravo Healthcare™ Announces Second Quarter 2021 Results Release Date and Conference Call Details
Miravo Healthcare™ to Present at Access to Giving Virtual Investor Conference
Miravo Healthcare™ to Present at Summer Solstice - Best Ideas from the Buy Side
Miravo Healthcare™ Announces Appointment of Mary Ritchie to its Board of Directors
Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders
Miravo Healthcare™ Announces First Quarter 2021 Results
Miravo Healthcare™ to Present at Q2 Virtual Investor Summit